Eli Lilly's shares rose after a study showed its weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy, with Zepbound patients losing about 20% of their weight compared to 14% for Wegovy. The study involved 751 participants and indicated Zepbound's potential for increased market share, generating $1.3 billion in sales in Q3. Both drugs are related to diabetes treatments. Teljes cikk (Euronews.com)